Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Imiquimod
Drug ID BADD_D01142
Description Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. Miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain types of skin cancer called superficial basal cell carcinoma.
Indications and Usage For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.
Marketing Status Prescription; Discontinued
ATC Code D06BB10
DrugBank ID DB00724
KEGG ID D02500
MeSH ID D000077271
PubChem ID 57469
TTD Drug ID D06CTE
NDC Product Code 22365-121; 51927-0168; 66039-829; 0395-8244; 0093-3133; 63629-8818; 64552-4008; 62147-0087; 51672-4145; 99207-270; 62350-0077; 99207-276; 68462-536; 62147-0072; 45802-368; 68682-272; 99207-260; 72189-084; 71052-160; 99207-271; 0168-0432; 51552-1538; 58175-0397; 11517-270; 72643-006; 11517-275; 51927-4898; 51672-4174; 11517-262
Synonyms Imiquimod | 1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine | S 26308 | S-26308 | R 837 | R-837 | R837 | Zyclara | Aldara
Chemical Information
Molecular Formula C14H16N4
CAS Registry Number 99011-02-6
SMILES CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.0020.004634%
Actinic keratosis23.01.06.0010.002317%Not Available
Agitation19.06.02.001; 17.02.05.0120.006952%
Alopecia23.02.02.001--
Angioedema23.04.01.001; 10.01.05.009--Not Available
Anorectal disorder07.03.01.001--Not Available
Anxiety19.06.02.002--
Aphthous ulcer07.05.06.0020.003476%Not Available
Application site erythema23.03.06.005; 12.07.01.001; 08.02.01.001--Not Available
Application site irritation12.07.01.003; 08.02.01.003--Not Available
Application site oedema08.02.01.020; 12.07.01.020--Not Available
Application site pain12.07.01.004; 08.02.01.004--Not Available
Application site pruritus23.03.12.004; 12.07.01.005; 08.02.01.005--Not Available
Application site rash12.07.01.016; 08.02.01.016; 23.03.13.008--Not Available
Application site reaction12.07.01.006; 08.02.01.006--Not Available
Application site ulcer23.07.03.010; 12.07.01.007; 08.02.01.007--Not Available
Application site warmth08.02.01.029; 12.07.01.029--Not Available
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.0010.008110%
Arthritis15.01.01.001--
Asthenia08.01.01.0010.009269%Not Available
Atrial fibrillation02.03.03.0020.003476%
Atrophic vulvovaginitis21.02.01.003--Not Available
Autoimmune hepatitis10.04.09.001; 09.01.07.0190.002317%Not Available
Back pain15.03.04.0050.006952%
Basal cell carcinoma23.08.02.001; 16.03.02.0010.003476%Not Available
Blindness17.17.01.003; 06.02.02.0010.002317%Not Available
Blister12.01.06.002; 23.03.01.0010.004634%Not Available
Blood glucose increased13.02.02.002--Not Available
Body temperature increased13.15.01.0010.002317%Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 12 Pages